- Home
- AAP vs DNLI Comparison
AAP vs DNLI Comparison
Compare AAP & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AAP | DNLI |
|---|---|---|
| Founded | 1929 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | 2002 | 2017 |
Fundamental Metrics
Financial Performance| Metric | AAP | DNLI |
|---|---|---|
| Price | $55.58 | $23.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 14 |
| Target Price | ★ $53.50 | $34.33 |
| AVG Volume (30 Days) | 1.8M | ★ 1.9M |
| Earning Date | 05-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | ★ 113.01 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $8,601,000,000.00 | N/A |
| Revenue This Year | $0.35 | N/A |
| Revenue Next Year | $2.51 | $408.85 |
| P/E Ratio | $136.97 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.89 | $12.58 |
| 52 Week High | $65.21 | $27.30 |
Technical Indicators
Market Signals| Indicator | AAP | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 46.89 | 45.21 |
| Support Level | $54.63 | $18.27 |
| Resistance Level | $61.73 | $23.27 |
| Average True Range (ATR) | 2.68 | 1.38 |
| MACD | -0.16 | -0.39 |
| Stochastic Oscillator | 46.13 | 17.58 |
Price Performance
Historical ComparisonAbout AAP Advance Auto Parts Inc.
Advance Auto Parts is a leading auto-parts retailer in North America with more than 4,000 store and branch locations. About half of the firm's sales are geared toward the professional channel, with the remaining sales in the do-it-yourself market. Through its vast store footprint and distribution network, Advance manages thousands of stock-keeping units for various vehicle makes and models. The retailer primarily competes on inventory availability and service speed, making the operating efficiency of its hub-and-spoke distribution model critical to meeting customer needs.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.